Company Overview and News

to your dashboard

Headline News

Week In Review: China's Creat To Restructure $1.5 Billion Biotest Takeover

2017-11-12 seekingalpha
Creat Group of China has withdrawn its current $1.5 billion offer to acquire Biotest (DE: BIOG) (OTC:BTTAY), a German blood plasma products corporation, because US regulators refused to approve the deal. According to Bloomberg, the Committee on Foreign Investment in the United States was worried that a China corporation would have access to US donor information. Creat and Biotest said the acquisition cannot be completed under the current structure, but the two companies hope to forge a new agreement that will satisfy US regulators. (166-1)

BioLife Solutions' (BLFS) CEO Mike Rice on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good day, ladies and gentlemen, and welcome to the Third Quarter 2017 BioLife Solutions Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (40-0)

ROTY Edition 1 Volume 48: Cutting A Position Loose And Promising Updates On Current Holdings

2017-11-08 seekingalpha
I remind readers the importance of constantly reevaluating current holdings in your brokerage accounts and questions to ask ourselves. (128-2)

ROTY Volume 1 Edition 44: Global Blood Therapeutics In Focus And Other Catalysts

2017-10-31 seekingalpha
I highlight Global Blood Therapeutics and recent results from the case study as indicative of further upside ahead. (110-4)

ROTY Volume 1 Edition 40: More Exciting Updates And Trades

2017-10-17 seekingalpha
I give a brief overview of predictive and reactive trading, noting how we incorporate both in ROTY. (352-7)

ROTY Volume 1 Edition 38: How I Decide When To Swap For A Contender And A New Trade

2017-10-10 seekingalpha
I continue to make small changes to the ROTY format in hopes of making the strategy easier for readers to implement and follow. (92-1)

ROTY Volume 1 Edition 35: Global Blood Therapeutics Setting Up, Zogenix´Offering And Trades

2017-10-03 seekingalpha
The stock of Global Blood Therapeutics should rise significantly higher in light of key presentations coming up. (74-1)

ROTY Volume 1 Edition 34: Zogenix Shines, Presentation Slides And Other Updates

2017-09-30 seekingalpha
ROTY had a great week and Zogenix was a big winner for us. Congratulations to those who had the patience to wait it out in spite of volatility. (334-2)

Cellular Biomedicine (CBMG) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow

2017-09-28 seekingalpha
The following slide deck was published by Cellular Biomedicine Group, Inc. in conjunction with this event. (1-0)

ROTY Volume 1 Edition 33: New Leadership In The Model Account, Changes To Format And Trades

2017-09-28 seekingalpha
I've made the switch to utilizing Tipranks Smart Portfolio for the ROTY model account and FinViz for tracking Contenders. (144-3)

ROTY Volume 1 Edition 32: Learning From Mistakes And Additional Trades

2017-09-21 seekingalpha
One of the ROTY full positions received a key analyst upgrade and has data coming soon. (59-2)

BioLife Solutions CryoStor® Cell Freeze Media Embedded in Cellular Biomedicine Group Clinical Trial of AlloJoin™

2017-09-19 prnewswire
BOTHELL, Wash., Sept. 19, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), announced that Cellular Biomedicine Group (NASDAQ: CBMG), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases ("CBMG"), has validated BioLife's proprietary CryoStor freeze media for use in CBMG's planned US Phase I clinical trial of AlloJoin, an off the shelf allogeneic stem cell therapy for knee osteoarthritis. (35-0)

Streetwise Reports Examines One Regenerative Medicine Firm to 'Keep a Close Eye On'

2017-08-18 marketwired
SAN FRANCISCO, CA--(Marketwired - August 18, 2017) - In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."

Hepatic Encephalopathy Pipeline Companies, Drug Profiles GR-3027, KLS-13019 and Ornithine Phenylacetate Report Available on

2017-06-09 prnewswire added Hepatic Encephalopathy - Pipeline Review, H1 2017 is new research report with 52 pages with latest updates, data and information to its online business intelligence library. (0-1)

Athersys: Initiating Coverage With Buy Rating And Price Target Of $8

2017-04-19 seekingalpha
The company has proprietary Multistem cell therapy technology (based on MAPCs, multipotent adult progenitor cells). The cell therapy technology is off-the-shelf (allogeneic).

CUSIP: 15117P102